KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to -$45.1 million.

  • Supernus Pharmaceuticals' Profit After Tax fell 21719.61% to -$45.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.1 million, marking a year-over-year decrease of 13201.53%. This contributed to the annual value of $73.9 million for FY2024, which is 551284.19% up from last year.
  • According to the latest figures from Q3 2025, Supernus Pharmaceuticals' Profit After Tax is -$45.1 million, which was down 21719.61% from $22.5 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Profit After Tax high stood at $38.5 million for Q3 2024, and its period low was -$45.1 million during Q3 2025.
  • Its 5-year average for Profit After Tax is $8.2 million, with a median of $7.9 million in 2022.
  • In the last 5 years, Supernus Pharmaceuticals' Profit After Tax soared by 249663.06% in 2024 and then crashed by 963790.32% in 2025.
  • Supernus Pharmaceuticals' Profit After Tax (Quarter) stood at $2.4 million in 2021, then skyrocketed by 943.45% to $25.5 million in 2022, then plummeted by 95.39% to $1.2 million in 2023, then soared by 1204.51% to $15.3 million in 2024, then plummeted by 394.34% to -$45.1 million in 2025.
  • Its last three reported values are -$45.1 million in Q3 2025, $22.5 million for Q2 2025, and -$11.8 million during Q1 2025.